Published in PLoS Med on April 18, 2006
Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg Infect Dis (2008) 2.24
Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res (2007) 1.52
Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res (2009) 1.27
Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res (2011) 1.22
Universal PCR assays for the differential detection of all Old World Leishmania species. Eur J Clin Microbiol Infect Dis (2010) 1.18
Protective and pathologic immune responses in human tegumentary leishmaniasis. Front Immunol (2012) 1.13
FcgammaRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions. Infect Immun (2007) 1.10
Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryot Cell (2006) 1.09
Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis (2008) 1.05
In vivo efficacy of gum obtained pistacia atlantica in experimental treatment of cutaneous leishmaniasis. Iran J Public Health (2010) 1.04
Miltefosine-induced apoptotic cell death on Leishmania major and L. tropica strains. Korean J Parasitol (2011) 1.01
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis (2009) 1.01
In Vitro Inhibitory Effect of Berberis vulgaris (Berberidaceae) and Its Main Component, Berberine against Different Leishmania Species. Iran J Parasitol (2014) 1.00
Impact of continuous axenic cultivation in Leishmania infantum virulence. PLoS Negl Trop Dis (2012) 1.00
Species typing in dermal leishmaniasis. Clin Microbiol Rev (2015) 0.97
Antimony resistance in leishmania, focusing on experimental research. J Trop Med (2011) 0.97
The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate. Parasitol Res (2011) 0.96
Old World Cutaneous Leishmaniasis and Refugee Crises in the Middle East and North Africa. PLoS Negl Trop Dis (2016) 0.94
Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl Trop Dis (2011) 0.93
Decreased effect of glucantime in cutaneous leishmaniasis complicated with secondary bacterial infection. Indian J Dermatol (2011) 0.90
Downregulation of Calcineurin Gene Is Associated with Glucantime(®) Resiatance in Leishmania infantum. Iran J Parasitol (2013) 0.90
Intracellular localization of the ABCC proteins of Leishmania and their role in resistance to antimonials. Antimicrob Agents Chemother (2009) 0.90
Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults. Am J Trop Med Hyg (2011) 0.88
Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials (2012) 0.87
Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS One (2013) 0.87
Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis. J Parasitol Res (2011) 0.86
Overexpression of ubiquitin and amino acid permease genes in association with antimony resistance in Leishmania tropica field isolates. Korean J Parasitol (2013) 0.86
Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance. Antimicrob Agents Chemother (2011) 0.85
Visceral leishmaniasis without fever in an 11-month-old infant: a rare clinical feature of Kala-azar. Korean J Parasitol (2014) 0.84
Detection of drug resistance gene in cutaneous leishmaniasis by PCR in some endemic areas of iran. Iran Red Crescent Med J (2011) 0.83
Transmission potential of antimony-resistant leishmania field isolates. Antimicrob Agents Chemother (2014) 0.81
Evaluation of the leishmanicidal and cytotoxic potential of essential oils derived from ten colombian plants. Iran J Parasitol (2013) 0.81
Antifungal, Antileishmanial, and Cytotoxicity Activities of Various Extracts of Berberis vulgaris (Berberidaceae) and Its Active Principle Berberine. ISRN Pharmacol (2014) 0.80
In vitro efficacy of ethanolic extract of Artemisia absinthium (Asteraceae) against Leishmania major L. using cell sensitivity and flow cytometry assays. J Parasit Dis (2014) 0.79
Heterogeneity of molecular resistance patterns in antimony-resistant field isolates of Leishmania species from the western Mediterranean area. Antimicrob Agents Chemother (2014) 0.79
Cutaneous leishmaniasis in suspected patients referred to the center for research and training in skin diseases and leprosy, tehran, iran from 2008 to 2011. Iran J Parasitol (2013) 0.79
A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions. Dermatol Res Pract (2016) 0.78
Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. PLoS One (2015) 0.78
Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul. PLoS Negl Trop Dis (2014) 0.78
Identification of differentially expressed proteins from Leishmania amazonensis associated with the loss of virulence of the parasites. PLoS Negl Trop Dis (2014) 0.78
Formation of linear amplicons with inverted duplications in Leishmania requires the MRE11 nuclease. PLoS Genet (2014) 0.78
Genetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from Afghanistan. PLoS Negl Trop Dis (2012) 0.77
Evaluation of Organelle Changes in Promastigotes of Unresponsive Leishmania Tropica to Meglumine Antimoniate in Comparison with Sensitive and Standard Isolates by Electron Microscopy. Indian J Dermatol (2015) 0.76
Comparison of Proteome Profiling of Two Sensitive and Resistant Field Iranian Isolates of Leishmania major to Glucantime® by 2- Dimensional Electrophoresis. Iran J Parasitol (2015) 0.75
Molecular docking and molecular dynamics simulation study of inositol phosphorylceramide synthase - inhibitor complex in leishmaniasis: Insight into the structure based drug design. F1000Res (2016) 0.75
Nonresponsiveness to standard treatment in cutaneous leishmaniasis: A case series from Sri Lanka. Trop Parasitol (2016) 0.75
MAPK1 of Leishmania donovani modulates antimony susceptibility by downregulating P-glycoprotein efflux pumps. Antimicrob Agents Chemother (2015) 0.75
Novel arylalkylamine compounds exhibits potent selective antiparasitic activity against Leishmania major. Bioorg Med Chem Lett (2015) 0.75
Leishmanicidal Activity of Films Containing Paromomycin and Gentamicin Sulfate both In Vitro and In Vivo. Iran J Parasitol (2011) 0.75
Gene regulation of pteridine reductase 1 in leishmania promastigotes and amastigotes using a full-length antisense construct. Iran J Parasitol (2013) 0.75
Molecular cloning, expression and enzymatic assay of pteridine reductase 1 from Iranian lizard Leishmania. Iran Biomed J (2010) 0.75
Visceral Leishmaniasis in Southwestern Iran: A Retrospective Clinico-Hematological Analysis of 380 Consecutive Hospitalized Cases (1999-2014). PLoS One (2016) 0.75
The activity of ozonated olive oil against Leishmania major promastigotes. Iran J Basic Med Sci (2015) 0.75
Effect of hydroalcoholic extract of Echinacea purpurea in combination with meglumine antimoniate on treatment of Leishmania major-induced cutaneous leishmaniasis in BALB/c mice. Int J Appl Basic Med Res (2017) 0.75
The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice. Iran J Basic Med Sci (2016) 0.75
Efficacy of Microwave and Infrared Radiation in the Treatment of the Skin Lesions Caused by Leishmania major in an Animal Model. Iran J Public Health (2012) 0.75
P-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER). Iran J Parasitol (2014) 0.75
Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate. Iran J Parasitol (2013) 0.75
Antigenic profile of heat-killed versus thimerosal-treated Leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Adv Biomed Res (2015) 0.75
Treatment Outcome of the Drug-resistant Zoonotic Cutaneous Leishmaniasis by Glucantime. Adv Biomed Res (2017) 0.75
Parasites and immunotherapy: with or against? J Parasit Dis (2014) 0.75
Biophysical and Pharmacological Characterization of Energy-Dependent Efflux of Sb in Laboratory-Selected Resistant Strains of Leishmania (Viannia) Subgenus. Front Cell Dev Biol (2017) 0.75
Medicinal plants with promising antileishmanial activity in Iran: a systematic review and meta-analysis. Ann Med Surg (Lond) (2017) 0.75
The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of Leishmania tropica. Iran J Parasitol (2017) 0.75
Computational design of molecular motors as nanocircuits in Leishmaniasis. F1000Res (2017) 0.75
The antileishmanial effects of Lowsonia inermis and Cedrus libani on Leishmania major promastigotes: an in vitro study. J Parasit Dis (2016) 0.75
Evaluation of Correlation between the In Vitro Susceptibility of Field Isolates of Leishmania major and Clinical Outcomes of Meglumine Antimoniate Therapy in Fars Province, Iran. J Arthropod Borne Dis (2017) 0.75
Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major. Parasitol Res (2015) 0.75
Iranian Native Plants on Treatment of Cutaneous Leishmaniosis: A Narrative Review. Iran J Parasitol (2017) 0.75
Advances in leishmaniasis. Lancet (2005) 8.95
Leishmaniasis. Lancet (1999) 7.20
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med (2002) 6.94
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health (2001) 3.08
Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis (1999) 2.92
Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. East Mediterr Health J (2005) 2.53
Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol (2000) 2.10
Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat (2004) 1.96
Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet (1998) 1.81
Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79
The amplified H circle of methotrexate-resistant leishmania tarentolae contains a novel P-glycoprotein gene. EMBO J (1990) 1.74
Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci U S A (1996) 1.74
An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis (1980) 1.70
Cutaneous leishmaniasis: clinical aspect. Clin Dermatol (1997) 1.67
In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother (1997) 1.67
Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today (1993) 1.64
Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J Biol Chem (2004) 1.60
Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem (2000) 1.54
A new focus of cutaneous leishmaniasis caused by Leishmania tropica. Saudi Med J (2002) 1.52
Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother (1998) 1.44
Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med (2001) 1.43
Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol (1999) 1.40
DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother (2001) 1.39
Clinical impact and relevance of antibiotic resistance. Adv Drug Deliv Rev (2005) 1.39
A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine (1999) 1.36
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res (2005) 1.36
Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol (2005) 1.35
Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother (2005) 1.34
High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system. Mol Biochem Parasitol (1994) 1.31
Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem J (2004) 1.30
Homologous recombination between direct repeat sequences yields P-glycoprotein containing amplicons in arsenite resistant Leishmania. Nucleic Acids Res (1993) 1.28
A new epidemic focus of zoonotic cutaneous leishmaniasis in central Iran. Ann Saudi Med (2004) 1.28
Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals (2003) 1.27
Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol Biochem Parasitol (2000) 1.24
New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology (1997) 1.24
Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother (2005) 1.24
Monitoring drug resistance in leishmaniasis. Trop Med Int Health (2001) 1.20
Genetic typing and phylogeny of the Leishmania donovani complex by restriction analysis of PCR amplified gp63 intergenic regions. Parasitology (2001) 1.18
Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res (2003) 1.16
Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994-95. Bull World Health Organ (1998) 1.16
The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob Agents Chemother (2003) 1.13
Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation. East Mediterr Health J (2003) 1.13
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother (2005) 1.12
Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate. Antimicrob Agents Chemother (1998) 1.12
Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun (2005) 1.11
Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitol Res (1994) 1.09
Pterin transport and metabolism in Leishmania and related trypanosomatid parasites. Int J Parasitol (2002) 1.07
Characterization of the folylpolyglutamate synthetase gene and polyglutamylation of folates in the protozoan parasite Leishmania. Mol Biochem Parasitol (2002) 0.94
Amplification of ABC transporter gene pgpA and of other heavy metal resistance genes in Leishmania tarentolae and their study by gene transfection and gene disruption. Methods Enzymol (1998) 0.89
Clinical significance of pneumococcal resistance and factors influencing outcomes. Treat Respir Med (2005) 0.83
Epidemiological aspects of canine visceral leishmaniosis in the Islamic Republic of Iran. Vet Parasitol (2005) 2.89
Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet (2009) 2.76
An observational study on the current distribution of visceral leishmaniasis in different geographical zones of Iran and implication to health policy. Travel Med Infect Dis (2011) 1.85
Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79
Genotyping of Acanthamoeba isolates from clinical and environmental specimens in Iran. Exp Parasitol (2008) 1.77
Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem (2003) 1.76
First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine (2008) 1.71
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine (2007) 1.66
Prefractionation by digitonin extraction increases representation of the cytosolic and intracellular proteome of Leishmania infantum. J Proteome Res (2006) 1.65
Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis (2006) 1.62
Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J Biol Chem (2004) 1.60
Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine (2009) 1.59
Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum. Am J Trop Med Hyg (2002) 1.56
A new focus of cutaneous leishmaniasis caused by Leishmania tropica. Saudi Med J (2002) 1.52
Use of tuf sequences for genus-specific PCR detection and phylogenetic analysis of 28 streptococcal species. J Clin Microbiol (2004) 1.51
Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species. BMC Genomics (2008) 1.47
Opium and risk of laryngeal cancer. Laryngoscope (2003) 1.42
Molecular identification and polymorphism determination of cutaneous and visceral leishmaniasis agents isolated from human and animal hosts in Iran. Biomed Res Int (2013) 1.41
Canine visceral leishmaniasis: asymptomatic infected dogs as a source of L. infantum infection. Acta Trop (2009) 1.40
Biochemical characterization of Leishmania major aquaglyceroporin LmAQP1: possible role in volume regulation and osmotaxis. Mol Microbiol (2007) 1.39
Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother (2007) 1.38
Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol (2008) 1.38
Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res (2009) 1.37
A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics (2006) 1.36
Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol (2005) 1.35
Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother (2003) 1.29
Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of Leishmania infantum. Mol Biochem Parasitol (2009) 1.28
Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. Parasitol Res (2008) 1.28
Emergence of a new focus of anthroponotic cutaneous leishmaniasis due to Leishmania tropica in rural communities of Bam district after the earthquake, Iran. Trop Med Int Health (2011) 1.28
Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals (2003) 1.27
Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res (2009) 1.27
Vector incrimination of sand flies in the most important visceral leishmaniasis focus in Iran. Am J Trop Med Hyg (2009) 1.25
Leishmania species: detection and identification by nested PCR assay from skin samples of rodent reservoirs. Exp Parasitol (2010) 1.25
Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis (2009) 1.25
A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum. Proteomics (2006) 1.24
Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother (2005) 1.24
Direct diagnosis of Leishmania species on serosity materials punctured from cutaneous leishmaniasis patients using PCR-RFLP. J Clin Lab Anal (2011) 1.23
Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucleic Acids Res (2011) 1.23
First report of a mixed infection due to Acanthamoeba genotype T3 and Vahlkampfia in a cosmetic soft contact lens wearer in Iran. Exp Parasitol (2009) 1.19
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol (2006) 1.18
Molecular characterization of Cryptosporidium isolates from humans and animals in Iran. Appl Environ Microbiol (2006) 1.17
Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res (2003) 1.16
Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother (2009) 1.15
CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis. PLoS Negl Trop Dis (2010) 1.14
Phlebotomus perfiliewi transcaucasicus is circulating both Leishmania donovani and L. infantum in northwest Iran. Exp Parasitol (2009) 1.14
Genome annotation and intraviral interactome for the Streptococcus pneumoniae virulent phage Dp-1. J Bacteriol (2010) 1.12
Identification and differentiation of Fasciola hepatica and Fasciola gigantica using a simple PCR-restriction enzyme method. Exp Parasitol (2009) 1.12
Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun (2005) 1.11
Trichomonas vaginalis: investigation of a novel diagnostic method in urine samples using cysteine proteinase 4 gene and PCR technique. Exp Parasitol (2010) 1.10
Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach. Exp Parasitol (2013) 1.10
Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryot Cell (2006) 1.09
Microfluidic device for rapid (<15 min) automated microarray hybridization. Clin Chem (2005) 1.06
Rapid detection of human Leishmania infantum infection: a comparative field study using the fast agglutination screening test and the direct agglutination test. Travel Med Infect Dis (2010) 1.06
Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006. Int J Dermatol (2010) 1.06
Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl Trop Dis (2012) 1.06
Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics (2011) 1.06
Development of species-specific PCR and PCR-restriction fragment length polymorphism assays for L.infantum/L.donovani discrimination. Exp Parasitol (2009) 1.05
The role of reduced pterins in resistance to reactive oxygen and nitrogen intermediates in the protozoan parasite Leishmania. Free Radic Biol Med (2008) 1.04
Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis (2008) 1.03
Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine (2006) 1.03
Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol (2005) 1.03
Interactions between BRCA2 and RAD51 for promoting homologous recombination in Leishmania infantum. Nucleic Acids Res (2012) 1.02
Phylogeny of the Enterobacteriaceae based on genes encoding elongation factor Tu and F-ATPase beta-subunit. Int J Syst Evol Microbiol (2005) 1.01
Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun (2002) 1.00
Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspot. Am J Hum Genet (2006) 1.00
Correlation between microarray DNA hybridization efficiency and the position of short capture probe on the target nucleic acid. Biotechniques (2005) 0.98
Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis. Exp Parasitol (2003) 0.97
A proteomic analysis of penicillin resistance in Streptococcus pneumoniae reveals a novel role for PstS, a subunit of the phosphate ABC transporter. Mol Microbiol (2005) 0.97
The gamma-glutamylcysteine synthetase gene of Leishmania is essential and involved in response to oxidants. Mol Microbiol (2009) 0.96
The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate. Parasitol Res (2011) 0.96
Echinococcus granulosus genotypes in livestock of Iran indicating high frequency of G1 genotype in camels. Exp Parasitol (2009) 0.96
Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains. J Proteome Res (2007) 0.96
Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial. J Drugs Dermatol (2005) 0.95
IgG avidity ELISA test for diagnosis of acute toxoplasmosis in humans. Korean J Parasitol (2012) 0.95
Characterization of the folylpolyglutamate synthetase gene and polyglutamylation of folates in the protozoan parasite Leishmania. Mol Biochem Parasitol (2002) 0.94
Ecological study and risk mapping of visceral leishmaniasis in an endemic area of Iran based on a geographical information systems approach. Geospat Health (2010) 0.94
Cutaneous and post kala-azar dermal leishmaniasis caused by Leishmania infantum in endemic areas of visceral leishmaniasis, northwestern Iran 2002-2011: a case series. Pathog Glob Health (2013) 0.94
Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol Cell Proteomics (2003) 0.94
Direct Effect of Two Naphthalene-Sulfonyl-Indole Compounds on Toxoplasma gondii Tachyzoite. J Parasitol Res (2013) 0.94
Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol Biochem Parasitol (2012) 0.94
Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl Trop Dis (2011) 0.93
Growth phase regulation of the main folate transporter of Leishmania infantum and its role in methotrexate resistance. J Biol Chem (2004) 0.92
Role of the ABC transporter PRP1 (ABCC7) in pentamidine resistance in Leishmania amastigotes. Antimicrob Agents Chemother (2007) 0.92
Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect Immun (2003) 0.92
Pneumocystis jirovecii Colonization in Non-HIV-Infected Patients Based on Nested-PCR Detection in Bronchoalveolar Lavage Samples. Iran J Public Health (2013) 0.91
Preparation and evaluation of a glycerol-preserved direct agglutination antigen for long-term preservation: a comparative study of the detection of anti-Leishmania infantum antibodies in human and dog. Asian Pac J Trop Med (2012) 0.91
The heat shock protein HSP70 and heat shock cognate protein HSC70 contribute to antimony tolerance in the protozoan parasite leishmania. Cell Stress Chaperones (2004) 0.91
Analysis of stage-specific expression of basic proteins in Leishmania infantum. J Proteome Res (2010) 0.91
Validation of a β-ME ELISA for detection of anti Leishmania donovani antibodies in Eastern Sudan. Iran J Immunol (2011) 0.91
Intracellular localization of the ABCC proteins of Leishmania and their role in resistance to antimonials. Antimicrob Agents Chemother (2009) 0.90